Did You Suffer Losses Investing in Tenax Therapeutics (TENX)?
A securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Tenax Therapeutics, Inc. (“Tenax” or the “Company”) (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”).
The action, Katz v. Tenax Therapeutics, Inc., et al., Case No. 1:26-cv-01264, was filed on October 26, 2026 in the U.S. District Court for the Middle District of North Carolina and seeks to recover damages caused by the Defendants’ alleged violations of the federal securities laws.
What Does the Tenax Securities Class Action Allege?
According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Defendants allegedly made false and/or misleading statements and/or failed to disclose that 1) TNX-103 was less effective than Defendants had led investors to believe; 2) accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and 3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial, stating that TNX-103 “did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.”
On this news, Tenax’s stock price fell approximately $12.06 per share, or 89.77%, to close at approximately $1.38 per share on August 10, 2026.
December 28, 2026 Lead Plaintiff Deadline
Tenax investors have until December 28, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.
Tenax Investors: Contact Kehoe Law Firm
If you purchased Tenax securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.
For a free, no-obligation legal evaluation, contact:
Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, as well as ERISA and retirement plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.
Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103